STOCK TITAN
  1. Home
  2. News
  3. ENOV

Enovis Corporation - ENOV STOCK NEWS

Welcome to our dedicated page for Enovis Corporation news (Ticker: ENOV), a resource for investors and traders seeking the latest updates and insights on Enovis Corporation stock.

Enovis Corporation (NYSE: ENOV) is a prominent player in the medical technology industry, dedicated to developing innovative solutions that improve patient outcomes and streamline healthcare workflows. Headquartered in Wilmington, DE, Enovis focuses on manufacturing and distributing high-quality medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy.

The company operates through two primary segments: Prevention & Recovery (P&R) and Reconstructive (Recon). The Prevention & Recovery segment, which generates the bulk of Enovis' revenue, is known for its extensive range of products aimed at injury prevention and patient rehabilitation. The Reconstructive segment offers advanced solutions for joint reconstruction surgeries, including knee, hip, and shoulder replacements.

Recent Achievements and Projects:

  • Enovis recently announced the offering of $400 million in Convertible Senior Notes due 2028, aimed at financing the acquisition of LimaCorporate S.p.A., enhancing their global footprint in orthopedic solutions.
  • The company's third-quarter 2023 financial results showcased a stable performance with revenues between $414 and $418 million, reflecting an 8-9% increase from the previous year.
  • Enovis continues to innovate, showcasing new technologies such as the Evolve34™ Lapidus Correction System and the EF1 External Fixation product line at the ACFAS annual meeting.

Enovis is committed to a culture of continuous improvement, leveraging its global talent and innovative capabilities to develop products that drive measurable patient outcomes. The company's dedication to excellence is evident in its comprehensive portfolio, which includes the DJO, LLC subsidiary known for its contributions to the foot and ankle care continuum.

In addition to its robust product development pipeline, Enovis is actively engaged in strategic acquisitions to enhance its market position and product offerings. The company's financial outlook for 2024 is positive, with expected revenues approximating $2.06-2.16 billion and adjusted EBITDA forecasted to be $368-383 million.

For more information, visit the Enovis Corporation website.

News

Enovis to Host Fourth Quarter and Full Year 2023 Conference Call on February 22nd

Rhea-AI Summary
Enovis Corporation (NYSE: ENOV) will host an investor conference call and webcast to discuss its fourth quarter and full year 2023 financial results on February 22, 2024. The company will also issue an earnings press release earlier that morning and make a presentation available on its website. Investors can access the live webcast via a link on the Enovis website and a replay will be available later that day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.39%
Tags
conferences
-
News

Enovis Introduces the DonJoy ROAM™ OA Knee Brace

Rhea-AI Summary
Enovis Corporation has announced the launch of its new DonJoy ROAM OA knee brace, designed to provide relief for patients with osteoarthritis or other knee pain and instability. The brace is equipped with patient-friendly features, such as magnetic clips, a 'Set-and-Forget' technology, BOA Fit System, and 2X Cool Technology fibers, making it comfortable and easy to use. The brace also offers a slim profile hinge design, dynamic strapping, and unique condyle harness to avoid sensitive skin, as well as anti-migration technology to keep the brace in place. The ROAM OA is designed to be effective for active patients with pain due to osteoarthritis or other causes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.46%
Tags
none
-
News

Orthofix Provides Executive Management Business Update and Appoints Julie Andrews as Chief Financial Officer

Rhea-AI Summary
Orthofix Medical Inc. (NASDAQ: OFIX) announced the appointment of Massimo Calafiore as President and CEO, effective immediately, and Julie Andrews as Chief Financial Officer, effective January 15, 2024. Calafiore brings extensive experience, and Andrews has a strong financial background. Catherine Burzik, Chair of the Board, expressed confidence in the new executives' vision and leadership. Calafiore stated his commitment to the company's mission and welcomed Andrews to the team.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.99%
Tags
management
News

Enovis Completes Acquisition of LimaCorporate S.p.A

Rhea-AI Summary
Enovis Corporation (NYSE: ENOV) announced the acquisition of LimaCorporate S.p.A., a global orthopedic leader, to strengthen its position in the orthopedic reconstruction market and accelerate global growth and margin expansion. The acquisition brings Enovis' recon segment to $1 billion in revenues and creates a fast-growing innovator in the global orthopedic reconstruction market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.16%
Tags
acquisition
-
News

Enovis to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
Enovis™ Corporation (NYSE: ENOV) to present at 42nd Annual J.P. Morgan Healthcare Conference on January 8th, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.18%
Tags
conferences
-
News

Enovis Announces Business Segment Leadership Transition Plan

Rhea-AI Summary
Enovis Corporation (NYSE: ENOV) announced the retirement of Brady R. Shirley, the President and COO, effective April 1, 2025. Louie Vogt and Terry Ross will be promoted to Group Presidents of the Reconstructive and Prevention & Recovery segments, respectively. Vogt and Ross will report to Enovis Chair and CEO, Matt Trerotola.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.88%
Tags
management
News

Orthofix Names Massimo Calafiore as President and Chief Executive Officer

Rhea-AI Summary
Orthofix Medical Inc. (OFIX) has announced the appointment of Massimo Calafiore as the incoming President and CEO. Mr. Calafiore, currently the CEO of LimaCorporate S.p.A., will take over in early 2024, following LimaCorporate's acquisition by Enovis Corporation. The board unanimously chose Mr. Calafiore for his proven track record in delivering value creation and extensive knowledge of the orthopedics and spine industry. His appointment is expected to drive significant profitable growth and enhance shareholder value for Orthofix.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.48%
Tags
none
-
News

Enovis to participate in the 6th Annual EverCore ISI HealthCONx Conference

Rhea-AI Summary
Enovis™ Corporation (NYSE: ENOV) Announces Participation in 6th Annual Evercore ISI HealthCONx Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.73%
Tags
conferences
-
News

Enovis Announces Third Quarter 2023 Results and Raises Full-Year Outlook

Rhea-AI Summary
Enovis Corporation (NYSE: ENOV) reported a 9% sales growth in the third quarter of 2023, with a net loss from continuing operations of $0.36 per share and adjusted earnings per diluted share of $0.56. The company increased its full-year growth and profit outlook, expecting a 7.4-7.6% organic revenue growth and adjusted EBITDA of $264-$270 million for 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.25%
Tags
earnings
News

Enovis™ to Showcase New Surgical Innovations at AAHKS Annual Meeting

Rhea-AI Summary
Enovis Corporation will showcase its latest technologies at the American Association of Hip and Knee Surgeons annual meeting. The company will unveil an updated ARVIS Augmented Reality System, EMPOWR blade stem, and EMPOWR 3D Knee. The ARVIS system now offers new features for precise implant alignment, rotation, and tissue balancing. The EMPOWR blade stem is designed to fit better than traditional blade stems and offers intraoperative efficiency. The EMPOWR 3D Knee is the first and only dual pivot total knee on the market, replicating natural motion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.67%
Tags
none

FAQ

What is the current stock price of Enovis Corporation (ENOV)?

The current stock price of Enovis Corporation (ENOV) is $43.12 as of December 20, 2024.

What is the market cap of Enovis Corporation (ENOV)?

The market cap of Enovis Corporation (ENOV) is approximately 2.4B.

What does Enovis Corporation specialize in?

Enovis Corporation specializes in developing medical technology solutions for reconstructive surgery, rehabilitation, pain management, and physical therapy.

What are the main operating segments of Enovis?

Enovis operates through two main segments: Prevention & Recovery (P&R) and Reconstructive (Recon).

What recent acquisitions has Enovis made?

Enovis is in the process of acquiring LimaCorporate S.p.A. and recently acquired Novastep® and the external fixation assets of D.N.E., LLC.

How did Enovis perform financially in the third quarter of 2023?

Enovis reported revenues between $414 and $418 million for Q3 2023, marking an 8-9% increase from the same period in 2022.

What new technologies has Enovis recently introduced?

Enovis introduced the Evolve34™ Lapidus Correction System and the EF1 External Fixation product line at the ACFAS annual meeting.

What is the financial outlook for Enovis in 2024?

Enovis expects revenues of approximately $2.06-2.16 billion and adjusted EBITDA of $368-383 million for the full year 2024.

What is the purpose of Enovis' recent offering of Convertible Senior Notes?

The offering aims to finance the acquisition of LimaCorporate S.p.A. and other general corporate purposes.

How does Enovis contribute to patient outcomes?

Enovis focuses on developing clinically differentiated solutions that improve patient outcomes and transform healthcare workflows.

What is the significance of the Prevention & Recovery segment for Enovis?

The P&R segment is crucial as it generates the majority of Enovis' revenue through products aimed at injury prevention and rehabilitation.

Who are the key contacts for investor and media relations at Enovis?

Investor Relations Contact: Kyle Rose, Vice President, Investor Relations. Media Contact: Katie Sweet, Vice President, Corporate Communications.

Stock ENOV logo
Enovis Corporation

NYSE:ENOV

ENOV Rankings

#1839 Ranked by Market Cap
N/A Ranked by Dividends

ENOV Stock Data

2.39B
55.33M
0.95%
110.96%
7.91%
Specialty Industrial Machinery
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States of America
WILMINGTON